نتائج البحث - "Glucose-Dependent Insulinotropic Peptide"

المساهمون: F. Folli, G. Finzi, R. Manfrini, A. Galli, F. Casiraghi, L. Centofanti, C. Berra, P. Fiorina, A. Davalli, S. La Rosa, C. Perego, P.B. Higgins

مصطلحات موضوعية: agonist, diabete, drug, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic peptide, incretin, islets of Langerhan, intracellular signal, mechanism, Settore MED/04 - Patologia Generale, Settore BIO/09 - Fisiologia

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37729025; volume:325; issue:5; firstpage:E595; lastpage:E609; numberofpages:15; journal:AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM; https://hdl.handle.net/2434/1026663Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85176271741

الإتاحة: https://doi.org/10.1152/ajpendo.00236.2023Test
https://hdl.handle.net/2434/1026663Test

View record in BASE

7

دورية أكاديمية

Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use ; Физиология, фармакология и перспективы применения ингибиторов дипептидилпептидазы-4

المساهمون: The work was supported by the Russian Science Foundation (Project No. 20-75-10013)., Работа выполнена при поддержке РНФ (проект № 20-75-10013).

المصدر: Pharmacy & Pharmacology; Том 11, № 1 (2023); 19-47 ; Фармация и фармакология; Том 11, № 1 (2023); 19-47 ; 2413-2241 ; 2307-9266 ; undefined

مصطلحات موضوعية: COVID-19, dipeptidyl peptidase 4, glucagonlike peptide-1, glucose-dependent insulinotropic peptide, sitagliptin, дипептидилпептидаза 4, глюкагоноподобный пептид-1, глюкозозависимый инсулинотропный пептид, ситаглиптин

وصف الملف: application/pdf

العلاقة: https://www.pharmpharm.ru/jour/article/view/1257/945Test; https://www.pharmpharm.ru/jour/article/view/1257/946Test; Дедов И.И., Шестакова М.В., Майоров А.Ю., Мокрышева Н.Г., Викулова О.К., Галстян Г.Р., Кураева Т.Л., Петеркова В.А., Смирнова О.М., Старостина Е.Г., Суркова Е.В., Сухарева О.Ю., Токмакова А.Ю., Шамхалова М.Ш., Ярек-Мартынова И.Я., Артемова Е.В., Бешлиева Д.Д., Бондаренко О.Н., Волеводз Н.Н., Гомова И.С., Григорян О.Р., Джемилова З.Н., Есаян Р.М., Ибрагимова Л.И., Калашников В.Ю., Кононенко И.В., Лаптев Д.Н., Липатов Д.В., Мельникова О.Г., Михина М.С., Мичурова М.С., Мотовилин О.Г., Никонова Т.В., Роживанов Р.В., Скляник И.А., Шестакова Е.А. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск // Сахарный диабет. – 2021. – Т. 24, № 1S. – С. 1–148.DOI:10.14341/DM12802; Sun H., Saeedi P., Karuranga S., Pinkepank M., Ogurtsova K., Duncan B.B., Stein C., Basit A., Chan J.C.N., Mbanya J.C., Pavkov M.E., Ramachandaran A., Wild S.H., James S., Herman W.H., Zhang P., Bommer C., Kuo S., Boyko E.J., Magliano D.J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 // Diabetes Res. Clin. Pract. – 2022. – Vol. 183. – Art. ID: 109119. DOI:10.1016/j.diabres.2021.109119; Hu Y., Chen Y. Overview of Type 2 Diabetes Drugs on the Market // J. Biosci. Med. – 2020. – Vol. 8, No. 8. – P. 1–14. DOI:10.4236/jbm.2020.88001.; Röhrborn D., Wronkowitz N., Eckel J. DPP4 in Diabetes // Front. Immunol. – 2015. – Vol. 6. – Art. ID: 386. DOI:10.3389/fimmu.2015.00386; Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action // Diabetes Care. – 2007. – Vol. 30, No. 6. – P. 1335–1343. DOI:10.2337/dc07-0228; Nabeno M., Akahoshi F., Kishida H., Miyaguchi I., Tanaka Y., Ishii S., Kadowaki T. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site // Biochem. Biophys. Res. Commun. – 2013. – Vol. 434, No. 2. – P. 191–196. DOI:10.1016/j.bbrc.2013.03.010; Matteucci E., Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme // Curr. Med. Chem. – 2009. – Vol. 16, No. 23. – P. 2943–2951. DOI:10.2174/092986709788803114; Saisho Y. Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions // Ann. Transl. Med. – 2018. – Vol. 6, No. 7. – Art. ID: 131. DOI:10.21037/atm.2018.02.24; Kubota S., Haraguchi T., Kuwata H., Seino Y., Murotani K., Tajima T., Terashima G., Kaneko M., Takahashi Y., Takao K., Kato T., Shide K., Imai S., Suzuki A., Terauchi Y., Yamada Y., Seino Y., Yabe D. Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan // J. Diabetes Investig. – 2023. – Vol. 14, No. 1. – P. 67–74. DOI:10.1111/jdi.13921; Dicembrini I., Montereggi C., Nreu B., Mannucci E., Monami M. Pancreatitis and pancreatic cancer in patients treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials // Diabetes Res. Clin. Pract. – 2020. – Vol. 159. – Art. ID: 107981. DOI:10.1016/j.diabres.2019.107981; Shao S., Xu Q., Yu X., Pan R., Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions // Pharmacol. Ther. – 2020. – Vol. 209. – Art. ID: 107503. DOI:10.1016/j.pharmthera.2020.107503; Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP // Best Pract. Res. Clin. Endocrinol. Metab. – 2009. – Vol. 23, No. 4. – P. 443–452. DOI:10.1016/j.beem.2009.03.005; Duez H., Cariou B., Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes // Biochem. Pharmacol. – 2012. – Vol. 83, No. 7. – P. 823–832. DOI:10.1016/j.bcp.2011.11.028; Uto A., Miyashita K., Endo S., Sato M., Ryuzaki M., Kinouchi K., Mitsuishi M., Meguro S., Itoh H. Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 Promoter // Endocrinology. – 2021. – Vol. 162, No. 12. – P. bqab193. DOI:10.1210/endocr/bqab193. Erratum in: Endocrinology. – 2022. – Vol. 163, No. 11.; Kosaraju J., Holsinger R.M.D., Guo L., Tam K.Y. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease // Mol. Neurobiol. – 2017. – Vol. 54, No. 8. – P. 6074–6084. DOI:10.1007/s12035-016-0125-7; Avogaro A., Fadini G.P. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors // Br. J. Clin. Pharmacol. – 2018. – Vol. 84, No. 8. – P. 1686–1695. DOI:10.1111/bcp.13611; Бирюкова Е.В., Шинкин М.В. Практика сахароснижающей терапии: выбор оптимального препарата из группы ингибиторов дипептидилпептидазы 4 // Эффективная фармакотерапия. – 2022. – Т. 18, № 6. – С. 20–30. DOI:10.33978/2307-3586-2022-18-6-20-30; Лазарева Н.Б. Ингибиторы дипептидилпептидазы-4: взгляд клинического фармаколога // Медицинский совет. – 2016. – № 19. – С. 114–121. DOI:10.21518/2079-701X-2016-19-114-121; Корбут А.И., Климонтов В.В. Терапия, основанная на инкретинах: почечные эффекты // Сахарный диабет. – 2016. – Т. 19, № 1. – C. 53–63. DOI:10.14341/DM7727; Gasbjerg L.S., Bergmann N.C., Stensen S., Christensen M.B., Rosenkilde M.M., Holst J.J., Nauck M., Knop F.K. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists // Peptides. – 2020. – Vol. 125. – Art. ID: 170183. DOI:10.1016/j.peptides.2019.170183; Deacon C.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus // Nat. Rev. Endocrinol. – 2020. – Vol. 16, No. 11. – P. 642–653. DOI:10.1038/s41574-020-0399-8; Kushwaha R.N., Haq W., Katti S.B. Discovery of 17 Gliptins in 17-Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview // Chemistry & Biology Interface. – 2014. – Vol. 4. – P. 137–162.; Goldenberg R., Gantz I., Andryuk P.J., O’Neill E.A., Kaufman K.D., Lai E., Wang Y.N., Suryawanshi S., Engel S.S. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy // Diabetes Obes. Metab. – 2017. – Vol. 19, No. 3. – P. 394–400. DOI:10.1111/dom.12832; Stoimenis D., Karagiannis T., Katsoula A., Athanasiadou E., Kazakos K., Bekiari E., Matthews D.R., Tsapas A. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis // Expert Opin. Pharmacother. – 2017. – Vol. 18, No. 9. – P. 843–851. DOI:10.1080/14656566.2017.1324848; Zou H., Zhu N., Li S. The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease // Expert Opin. Ther. Targets. – 2020. – Vol. 24, No. 2. – P. 147–153. DOI:10.1080/14728222.2020.1721468; Anderluh M., Kocic G., Tomovic K., Kocic H., Smelcerovic A. DPP-4 inhibition: А novel therapeutic approach to the treatment of pulmonary hypertension? // Pharmacol. Ther. – 2019. – Vol. 201. – P. 1–7. DOI:10.1016/j.pharmthera.2019.05.007; Zhang S., Li P., Xin M., Jin X., Zhao L., Nan Y., Cheng X.W. Dipeptidyl peptidase-4 inhibition prevents lung injury in mice under chronic stress via the modulation of oxidative stress and inflammation // Exp. Anim. – 2021. – Vol. 70, No. 4. – P. 541–552. DOI:10.1538/expanim.21-0067; Patel P.M., Jones V.A., Kridin K., Amber K.T. The role of Dipeptidyl Peptidase-4 in cutaneous disease // Exp. Dermatol. – 2021. – Vol. 30, No. 3. – P. 304–318. DOI:10.1111/exd.14228; Tasic T., Bäumer W., Schmiedl A., Schwichtenhövel F., Pabst R., Raap U., von Hörsten S., Stephan M. Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis // Clin. Exp. Allergy. – 2011. – Vol. 41, No. 8. – P. 1098–1107. DOI:10.1111/j.1365-2222.2011.03778.x; Kridin K., Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients // JAMA Dermatol. – 2018. – Vol. 154, No. 10. – P. 1152–1158. DOI:10.1001/jamadermatol.2018.2352; Huang J., Liu X., Wei Y., Li X., Gao S., Dong L., Rao X., Zhong J. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease // Front Immunol. – 2022. – Vol. 13. – Art. ID: 830863. DOI:10.3389/fimmu.2022.830863; Guo Q., Zhang S., Huang J., Liu K. Alogliptin inhibits IL-1β-induced inflammatory response in fibroblast-like synoviocytes // Int. Immunopharmacol. – 2020. – Vol. 83. – Art. ID: 106372. DOI:10.1016/j.intimp.2020.106372; Han C.K., Lee W.F., Hsu C.J., Huang Y.L., Lin C.Y., Tsai C.H., Huang C.C., Fong Y.C., Wu M.H., Liu J.F., Tang C.H. DPP4 reduces proinflammatory cytokine production in human rheumatoid arthritis synovial fibroblasts // J. Cell Physiol. – 2021. – Vol. 236, No. 12. – P. 8060–8069. DOI:10.1002/jcp.30494; Jackson E.K. Context-dependent effects of dipeptidyl peptidase 4 inhibitors // Curr. Opin. Nephrol. Hypertens. – 2017. – Vol. 26, No.2. – P. 83–90. DOI:10.1097/MNH.0000000000000303; Gupta S., Sen U. More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling // Pharmacol Res. – 2019. – Vol. 147. – P. 104391. DOI:10.1016/j.phrs.2019.104391; Allada R., Ren J., Restrepo R., Nistala R. Role of Dipeptidyl Peptidase 4 and Effects of a Western Diet in Renal Sodium Transport and Tubular Injury // FASEB. – 2022. – Vol. 36, No. S1. DOI:10.1096/fasebj.2022.36.s1.r5683; Min H.S., Kim J.E., Lee M.H., Song H.K., Kang Y.S., Lee M.J., Lee J.E., Kim H.W., Cha J.J., Chung Y.Y., Hyun Y.Y., Han J.Y., Cha D.R. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction // Lab. Invest. – 2014. – Vol. 94, No. 6. – P. 598–607. DOI:10.1038/labinvest.2014.50; O’Leary H., Ou X., Broxmeyer H.E. The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation // Curr. Opin. Hematol. – 2013. – Vol. 20, No. 4. – P. 314–319. DOI:10.1097/MOH.0b013e32836125ac; Bae J.C. DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once? // Endocrinol. Metab (Seoul). – 2022. – Vol. 37, No. 6. – P. 858–860. DOI:10.3803/EnM.2022.605; Jung E., Kim J., Kim C.S., Kim S.H., Cho M.H. Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy // Biochim. Biophys. Acta. – 2015. – Vol. 1852, No. 12. – P. 2618–2629. DOI:10.1016/j.bbadis.2015.09.010; Avogaro A., Fadini G.P. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications // Diabetes Care. – 2014. – Vol. 37, No. 10. – P. 2884–2894. DOI:10.2337/dc14-0865; Bazhin A.A., Chambon M., Vesin J., Bortoli J., Collins J.W., Turcatti G., Chou C.J., Goun E.A. A Universal Assay for Aminopeptidase Activity and Its Application for Dipeptidyl Peptidase-4 Drug Discovery // Anal. Chem. – 2019. – Vol. 91, No. 1. – P. 1098–1104. DOI:10.1021/acs.analchem.8b04672; Méndez L.R., Arrebola Y., Valdés-Tresanco M.E., Díaz-Guevara L., Bergado G., Sánchez B., Charli J.L., Pascual Alonso I. Bestatin and bacitracin inhibit porcine kidney cortex dipeptidyl peptidase IV activity and reduce human melanoma MeWo cell viability // Int. J. Biol. Macromol. – 2020. – Vol. 164. – P. 2944–2952. DOI:10.1016/j.ijbiomac.2020.08.157; Chittepu V.C.S.R., Kalhotra P., Osorio-Gallardo T., Jiménez-Martínez C., Torre R.R.R., Gallardo-Velazquez T., Osorio-Revilla G. New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxytocin // Molecules. – 2019. – Vol. 24, No. 21. – Art. ID: 3887. DOI:10.3390/molecules24213887; Gao J., Gong H., Mao X. Dipeptidyl Peptidase-IV Inhibitory Activity and Related Molecular Mechanism of Bovine α-Lactalbumin-Derived Peptides // Molecules. – 2020. – Vol. 25, No. 13. – Art. ID: 3009. DOI:10.3390/molecules25133009; Huang P.K., Lin S.R., Chang C.H., Tsai M.J., Lee D.N., Weng C.F. Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV // Sci. Rep. – 2019. – Vol. 9, No. 1. – Art. ID: 15585. DOI:10.1038/s41598-019-52088-7; Wang J., Dai G., Li W. Berberine regulates glycemia via local inhibition of intestinal dipeptidyl peptidase-IV // Zhejiang Da Xue Xue Bao Yi Xue Ban. – 2016. – Vol. 45, No. 5. – P. 486–492. DOI:10.3785/j.issn.1008-9292.2016.09.06. Chinese; Kalhotra P., Chittepu V.C.S.R., Osorio-Revilla G., Gallardo-Velazquez T. Phytochemicals in Garlic Extract Inhibit Therapeutic Enzyme DPP-4 and Induce Skeletal Muscle Cell Proliferation: A Possible Mechanism of Action to Benefit the Treatment of Diabetes Mellitus // Biomolecules. – 2020. – Vol. 10, No. 2. – Art. ID: 305. DOI:10.3390/biom10020305; Narayanan N., Naik D., Sahoo J., Kamalanathan S. Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control // World J Virol. – 2022. – Vol. 11, No. 6. – P. 399–410. DOI:10.5501/wjv.v11.i6.399; Ортенберг Э.А., Суплотова Л.А. Ингибиторы дипептидилпептидазы-4: очевидное и вероятное (обзор литературы) // Медицинский совет. – 2022. – Т. 16, № 10. – С. 40–45. DOI:10.21518/2079-701X-2022-16-10-40-45; Vankadari N., Wilce J.A. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 // Emerg. Microbes. Infect. – 2020. – Vol. 9, No. 1. – P. 601–604. DOI:10.1080/22221751.2020.1739565; Li Y., Zhang Z., Yang L., Lian X., Xie Y., Li S., Xin S., Cao P., Lu J. The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike // iScience. – 2020. – Vol. 23, No. 6. – Art. ID: 101160. DOI:10.1016/j.isci.2020.101160. Erratum in: iScience. – 2020. – Vol. 23, No. 8. – Art. ID: 101400.; Sebastián-Martín A., Sánchez B.G., Mora-Rodríguez J.M., Bort A., Díaz-Laviada I. Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology // Biomedicines. – 2022. – Vol. 10, No. 8. – Art. ID: 2026. DOI:10.3390/biomedicines10082026; Krejner-Bienias A., Grzela K., Grzela T. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End? // Arch Immunol Ther Exp (Warsz). – 2021. – Vol. 69, No. 1. – P. 1. DOI:10.1007/s00005-020-00602-5; Dastan F., Abedini A., Shahabi S., Kiani A., Saffaei A., Zare A. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung // Iran J. Allergy Asthma Immunol. – 2020. – Vol. 19, No. S1. – P. 10–12. DOI:10.18502/ijaai.v19i(s1.r1).2849; Schlicht K., Rohmann N., Geisler C., Hollstein T., Knappe C., Hartmann K., Schwarz J., Tran F., Schunk D., Junker R., Bahmer T., Rosenstiel P., Schulte D., Türk K., Franke A., Schreiber S., Laudes M. Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections // Int. J. Obes. (Lond). – 2020. – Vol. 44, No. 11. – P. 2335–2338. DOI:10.1038/s41366-020-00689-y. Erratum in: Int. J. Obes. (Lond). – 2022. – Vol. 46, No. 1. – Art. ID: 243.; Varin E.M., Mulvihill E.E., Beaudry J.L., Pujadas G., Fuchs S., Tanti J.F., Fazio S., Kaur K., Cao X., Baggio L.L., Matthews D., Campbell J.E., Drucker D.J. Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition // Cell Metab. – 2019. – Vol. 29, No. 2. – P. 320–334.e5. DOI:10.1016/j.cmet.2018.10.001; Kifle Z.D., Woldeyohanin A.E., Demeke C.A. SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19 // Metabol. Open. – 2021. – Vol. 12. – Art. ID: 100134. DOI:10.1016/j.metop.2021.100134; Soare A., Györfi H.A., Matei A.E., Dees C., Rauber S., Wohlfahrt T., Chen C.W., Ludolph I., Horch R.E., Bäuerle T., von Hörsten S., Mihai C., Distler O., Ramming A., Schett G., Distler J.H.W. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis // Arthritis. Rheumatol. – 2020. – Vol. 72, No. 1. – P. 137–149. DOI:10.1002/art.41058; Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., Dietrich B., Golor G., Schrodter A., Keymeulen B., Lasseter K.C., Kipnes M.S., Snyder K., Hilliard D., Tanen M., Cilissen C., De Smet M., de Lepeleire I., Van Dyck K., Wang A.Q., Zeng W., Davies M.J., Tanaka W., Holst J.J., Deacon C.F., Gottesdiener K.M., Wagner J.A. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes // J. Clin. Endocrinol. Metab. – 2006. – Vol. 91, No. 11. – P. 4612–4619. DOI:10.1210/jc.2006-1009; Hou L., Zhao T., Liu Y., Zhang Y. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis // Exp. Ther. Med. – 2015. – Vol. 9, No. 4. – P. 1528–1536. DOI:10.3892/etm.2015.2277; Hayes J., Anderson R., Stephens J.W. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy // Drug Des. Devel. Ther. – 2016. – Vol. 10. – P. 2263–2270. DOI:10.2147/DDDT.S93076; Fonseca V., Staels B., Morgan J.D. 2nd, Shentu Y., Golm G.T., Johnson-Levonas A.O., Kaufman K.D., Goldstein B.J., Steinberg H. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes // J. Diabetes Complications. – 2013. – Vol. 27, No. 2. – P. 177–183. DOI:10.1016/j.jdiacomp.2012.09.007; Шестакова М.В. Опыт применения ситаглиптина (первого ингибитора ДПП-4) в лечении сахарного диабета 2 типа в российской федерации: результаты наблюдательной программы «Диа-Да» // Сахарный диабет. – 2010. – Т. 13, № 3. – С. 57–60. DOI:10.14341/2072-0351-5489; Аметов А.С., Гусенбекова Д.Г. Роль ингибиторов ДПП-4 в коррекции нарушений жирового обмена у пациентов с СД 2 типа и ожирением // Сахарный диабет. – 2015. – Т. 18, № 3. – С. 85–92. DOI:10.14341/DM2015385-92; Павлова М.Г. Вилдаглиптин - новые возможности в терапии сахарного диабета 2 типа // Фарматека. – 2022. – Т. 29, № 11/12. – С. 36–40. DOI:10.18565/pharmateca.2022.11-12.36-40; Azuma K., Rádiková Z., Mancino J., Toledo F.G., Thomas E., Kangani C., Dalla Man C., Cobelli C., Holst J.J., Deacon C.F., He Y., Ligueros-Saylan M., Serra D., Foley J.E., Kelley D.E. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes // J. Clin. Endocrinol. Metab. – 2008. – Vol. 93, No. 2. – P. 459–464. DOI:10.1210/jc.2007-1369; Odawara M., Sagara R. Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan // J. Diabetes Metab. Disord. – 2016. – Vol. 15. – Art. ID: 21. DOI:10.1186/s40200-016-0240-z; Аметов А.С. Галвус. 5 лет в России // Эндокринология. Новости. Мнения. Обучение. – 2014. – № 3 (8). – С. 10–16.; Kosaraju J., Murthy V., Khatwal R.B., Dubala A., Chinni S., Muthureddy Nataraj S.K., Basavan D. Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer’s disease // J. Pharm. Pharmacol. – 2013. – Vol. 65, No. 12. – P. 1773–1784. DOI:10.1111/jphp.12148; Arruda-Junior D.F., Martins F.L., Dariolli R., Jensen L., Antonio E.L., Dos Santos L., Tucci P.J., Girardi A.C. Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure // Front Physiol. – 2016. – Vol. 7. – Art. ID: 293. DOI:10.3389/fphys.2016.00293; O’Farrell A.M., van Vliet A., Abou Farha K., Cherrington J.M., Campbell D.A., Li X., Hanway D., Li J., Guler H.P. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects // Clin. Ther. – 2007. – Vol. 29, No. 8. – P. 1692–1705. DOI:10.1016/j.clinthera.2007.08.005; Lotfy M., Singh J., Kalász H., Tekes K., Adeghate E. Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus // Open Med. Chem. J. – 2011. – Vol. 5, No. 2. – P. 82–92. DOI:10.2174/1874104501105010082; Pattzi H.M., Pitale S., Alpizar M., Bennett C., O’Farrell A.M., Li J., Cherrington J.M., Guler H.P., PHX1149-PROT202 Study Group. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial // Diabetes Obes. Metab. – 2010. – Vol. 12, No. 4. – P. 348–355. DOI:10.1111/j.1463-1326.2010.01195.x; Garcia-Soria G., Gonzalez-Galvez G., Argoud G.M., Gerstman M., Littlejohn T.W. 3rd, Schwartz S.L., O’Farrell A.M., Li X., Cherrington J.M., Bennett C., Guler H.P. The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus // Diabetes Obes. Metab. – 2008. – Vol. 10, No. 4. – P. 293–300. DOI:10.1111/j.1463-1326.2008.00868.x; Schenk R., Nix D. TCT-180 Impact of the novel DPP-IV-inhibitor Dutogliptin in combination with G-CSF on survival rates and cardiac remodelling after acute myocardial infarction // J. Am. Coll. Cardiol. – 2016. – Vol. 68, Suppl. 18. – Art. ID: B74. DOI:10.1016/j.jacc.2016.09.322; Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes // Diabetes Obes. Metab. – 2008. – Vol. 10, No. 5. – P. 376–386. DOI:10.1111/j.1463-1326.2008.00876.x; Matthaei S., Aggarwal N., Garcia-Hernandez P., Iqbal N., Chen H., Johnsson E., Chin A., Hansen L. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin // Diabetes Obes. Metab. – 2016. – Vol. 18, No. 11. – P. 1128–1133. DOI:10.1111/dom.12741; Chacra A.R., Tan G.H., Apanovitch A., Ravichandran S., List J., Chen R.; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial // Int. J. Clin. Pract. – 2009. – Vol. 63, No. 9. – P. 1395–1406. DOI:10.1111/j.1742-1241.2009.02143.x. Erratum in: Int. J. Clin. Pract. – 2010. – Vol. 64, No. 2. –Art. ID: 277.; Huang J., Jia Y., Sun S., Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system // BMC Pharmacol. Toxicol. – 2020. – Vol. 21, No. 1. – Art. ID: 68. DOI:10.1186/s40360-020-00447-w; Петунина Н.А., Бращенкова А.В. Саксаглиптин в концепции эффективного управления сахарным диабетом 2 типа // Фарматека. – 2011. – № 16 (229). – С. 12–19.; Kosaraju J., Gali C.C., Khatwal R.B., Dubala A., Chinni S., Holsinger R.M., Madhunapantula V.S., Muthureddy Nataraj S.K., Basavan D. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer’s disease // Neuropharmacology. – 2013. – Vol. 72. – P. 291–300. DOI:10.1016/j.neuropharm.2013.04.008; Verspohl E.J. Novel pharmacological approaches to the treatment of type 2 diabetes // Pharmacol. Rev. – 2012. – Vol. 64, No. 2. – P. 188–237. DOI:10.1124/pr.110.003319; Del Prato S., Barnett A.H., Huisman H., Neubacher D., Woerle H.J., Dugi K.A. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial // Diabetes Obes Metab. – 2011. – Vol. 13, No. 3. – P. 258–267. DOI:10.1111/j.1463-1326.2010.01350.x; Taskinen M.R., Rosenstock J., Tamminen I., Kubiak R., Patel S., Dugi K.A., Woerle H.J. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study // Diabetes Obes Metab. – 2011. – Vol. 13, No. 1. – P. 65–74. DOI:10.1111/j.1463-1326.2010.01326.x; Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U., Friedrich C., Herbach K., Woerle H.J., Dugi K.A. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes // Diabet Med. – 2010. – Vol. 27, No. 12. – P. 1409–1419. DOI:10.1111/j.1464-5491.2010.03131.x; Owens D.R., Swallow R., Dugi K.A., Woerle H.J. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study // Diabet. Med. 2011. – Vol. 28, No. 11. – P. 1352–1361. DOI:10.1111/j.1464-5491.2011.03387.x. Erratum in: Diabet. Med. – 2012. – Vol. 29, No. 1. – Art. ID: 158.; Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., Dugi K.A., Woerle H.J. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial // Lancet. – 2012. – Vol. 380, No. 9840. – P. 475–483. DOI:10.1016/S0140-6736(12)60691-6; Gupta R., Walunj S.S., Tokala R.K., Parsa K.V., Singh S.K., Pal M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes // Curr. Drug. Targets. – 2009. – Vol. 10, No. 1. – P. 71–87. DOI:10.2174/138945009787122860; DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q., Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study // Diabetes Care. – 2008. – Vol. 31, No. 12. – P. 2315–2317. DOI:10.2337/dc08-1035; Rosenstock J., Rendell M.S., Gross J.L., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia // Diabetes Obes. Metab. – 2009. – Vol. 11, No. 12. – P. 1145–1152. DOI:10.1111/j.1463-1326.2009.01124.x; Chen X.W., He Z.X., Zhou Z.W., Yang T., Zhang X., Yang Y.X., Duan W., Zhou S.F. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus // Clin. Exp. Pharmacol. Physiol. – 2015. – Vol. 42, No. 10. – P. 999–1024. DOI:10.1111/1440-1681.12455; Pratley R.E., Reusch J.E., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study // Curr. Med. Res. Opin. – 2009. – Vol. 25, No. 10. – P. 2361–2371. DOI:10.1185/03007990903156111; Trujillo J.M., Wettergreen S.A., Nuffer W.A., Ellis S.L.,McDermott M.T. Cardiovascular Outcomes of New Medications for Type 2 Diabetes // Diabetes Technol. Ther. – 2016. – Vol. 18, No. 12. – P. 749–758. DOI:10.1089/dia.2016.0295; Мкртумян А.М. Алоглиптин – эффективный и безопасный ингибитор дипептидилпептидазы-4 в терапии больных сахарным диабетом 2 типа // Фарматека. – 2015. – № 5 (298). – С. 20–27.; Мкртумян А.М., Егшатян Л.В. Алоглиптин – высокоселективный ингибитор ДПП-4 с фокусом на кардиоваскулярную безопасность // Медицинский совет. – 2016. – № 5. – С. 104–107. DOI:10.21518/2079-701X-2016-05-104-107; Kim S.H., Jung E., Yoon M.K., Kwon O.H., Hwang D.M., Kim D.W., Kim J., Lee S.M., Yim H.J. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo // Eur. J. Pharmacol. – 2016. – Vol. 788. – P. 54–64. DOI:10.1016/j.ejphar.2016.06.016; Rhee E.J., Lee W.Y., Yoon K.H., Yoo S.J., Lee I.K., Baik S.H., Kim Y.K., Lee M.K., Park K.S., Park J.Y., Cha B.S., Lee H.W., Min K.W., Bae H.Y., Kim MJ, Kim J.A., Kim D.K., Kim S.W. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes // Diabetes Obes. Metab. – 2010. – Vol. 12, No. 12. – P. 1113–1119. DOI:10.1111/j.1463-1326.2010.01303.x; Lim S., Han K.A., Yu J., Chamnan P., Kim E.S., Yoon K.H., Kwon S., Moon M.K., Lee K.W., Kim D.J., Kim M., Wongtanate M., Kim E.Y., Kim S.H., Lee M.K., INICOM Study Group. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) // Diabetes Obes. Metab. – 2017. – Vol. 19, No. 1. – P. 87–97. DOI:10.1111/dom.12787; Maladkar M., Sankar S., Kamat K. Teneligliptin: heralding change in type 2 diabetes // J. Diabetes Mellitus. – 2016. – Vol. 6. – P. 113–131. DOI:10.4236/jdm.2016.62012; Kadowaki T., Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus // Diabetes Obes Metab. – 2013. – Vol. 15, No. 9. – P. 810–818. DOI:10.1111/dom.12092; Otsuki H., Kosaka T., Nakamura K., Shimomura F., Kuwahara Y., Tsukamoto T. Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes // Int Urol Nephrol. – 2014. – Vol. 46, No. 2. – P. 427–432. DOI:10.1007/s11255-013-0552-6; Hashikata T., Yamaoka-Tojo M., Kakizaki R., Nemoto T., Fujiyoshi K., Namba S., Kitasato L., Hashimoto T., Kameda R., Maekawa E., Shimohama T., Tojo T., Ako J. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes // Heart Vessels. – 2016. – Vol. 31, No. 8. – P. 1303–1310. DOI:10.1007/s00380-015-0724-7. Erratum in: Heart Vessels. – 2016. – Vol. 31, No. 8. – P. 1311–1312.; Kadowaki T., Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension // Diabetes Obes. Metab. – 2014. – Vol. 16, No. 5. – P. 418–425. DOI:10.1111/dom.12235; Kadowaki T., Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus // J. Diabetes Investig. – 2013. – Vol. 4, No. 6. – P. 576–584. DOI:10.1111/jdi.12092; Kim M.K., Rhee E.J., Han K.A, Woo A.C., Lee M.K., Ku B.J., Chung C.H., Kim K.A., Lee H.W., Park I.B., Park J.Y., ChulJang H.C., Park K.S., Jang W.I., Cha B.Y. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial // Diabetes Obes Metab. – 2015. – Vol. 17, No. 3. – P. 309–312. DOI:10.1111/dom.12424; Tanaka K., Okada Y., Mori H., Inada Y., Suzuka K., Uriu K., Tanaka Y. Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study // Diabetol. Int. – 2016. – Vol. 7, No. 4. – P. 368–374. DOI:10.1007/s13340-016-0258-y; Furuta S., Smart C., Hackett A., Benning R., Warrington S. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans // Xenobiotica. – 2013. – Vol. 43, No. 5. – P. 432–442. DOI:10.3109/00498254.2012.731618; Kaku K. Dose-ranging study of anagliptin in Japanese patients with type 2 diabetes: a multi-centre, randomized, placebo-controlled, double-blind, parallel-group study // Jpn Pharmacol Ther. – 2012. – Vol. 40. – P. 973–984.; Yang H.K., Min K.W., Park S.W., Chung C.H., Park K.S., Choi S.H., Song K.H., Kim D.M., Lee M.K., Sung Y.A., Baik S.H., Kim I.J., Cha B.S., Park J.H., Ahn Y.B., Lee I.K., Yoo S.J., Kim J., Park Ie.B., Park T.S., Yoon K.H. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes // Endocr. J. – 2015. – Vol. 62, No. 5. – P. 449–462. DOI:10.1507/endocrj.EJ14-0544; Kakuda H., Kobayashi J., Kakuda M., Yamakawa J., Takekoshi N. The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes // Endocrine. – 2015. – Vol. 48, No. 3. – P. 1005–1009. DOI:10.1007/s12020-014-0376-x; Kaku K. Efficacy and safety of anagliptin add-on therapy in Japanese patients with type 2 diabetes // Jpn Pharmacol Ther. – 2012. – Vol. 40, No. 9. – P. 745–770.; Burness C.B. Omarigliptin: first global approval // Drugs. – 2015. – Vol. 75, No. 16. – P. 1947–1952. DOI:10.1007/s40265-015-0493-8; Sheu W.H., Gantz I., Chen M., Suryawanshi S., Mirza A., Goldstein B.J., Kaufman K.D., Engel S.S. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes // Diabetes Care. – 2015. – Vol. 38, No. 11. – P. 2106–2114. DOI:10.2337/dc15-0109; Evans P.M., Bain S.C. Omarigliptin for the treatment of type 2 diabetes mellitus // Expert. Opin. Pharmacother. – 2016. – Vol. 17, No. 14. – P. 1947–1952. DOI:10.1080/14656566.2016.1218472; Tan X. Omarigliptin for the treatment of type 2 diabetes // Endocrine. – 2016. – Vol. 54, No. 1. – P. 24–31. DOI:10.1007/s12020-016-1011-9; Sharma R., Sun H., Piotrowski D.W, Ryder T.F., Doran S.D., Dai H., Prakash C. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human // Drug Metab. Dispos. – 2012. – Vol. 40, No. 11. – P. 2143–2161. DOI:10.1124/dmd.112.047316; Muto C., Dai H., Teeter J.G., Johnson S., Cropp A.B., Chiba K., Suwa T. The pharmacokinetics and pharmacodynamics of PF-00734200, a DPP-IV inhibitor, in healthy Japanese subjects // Int J Clin Pharmacol Ther. – 2012. – Vol. 50, No. 7. – P. 505–509. DOI:10.5414/CP201614; Rosenstock J., Lewin A.J., Norwood P., Somayaji V., Nguyen T.T., Teeter J.G., Johnson S.L., Dai H., Terra S.G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes // Diabet. Med. – 2011. – Vol. 28, No. 4. – P. 464–469. DOI:10.1111/j.1464-5491.2010.03181.x; Terra S.G., Somayaji V., Schwartz S., Lewin A.J., Teeter J.G., Dai H., Nguyen T.T., Calle R.A. A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes // Exp. Clin. Endocrinol. Diabetes. – 2011. – Vol. 119, No. 7. – P. 401–407. DOI:10.1055/s-0031-1273737; Галстян К.О., Недосугова Л.В., Петунина Н.А., Трахтенберг Ю.А., Востокова Н.В., Караваева О.В., Часовская Т.Е. Первый отечественный ингибитор ДПП-4 госоглиптин в сравнении с вилдаглиптином при лечении пациентов с сахарным диабетом 2 типа // Сахарный диабет. – 2016. – Т. 19, № 1. – С. 89–96. DOI:10.14341/DM7233; McKeage K. Trelagliptin: First Global Approval // Drugs. – 2015. – Vol. 75, No. 10. – P. 1161–1164. DOI:10.1007/s40265-015-0431-9; Grimshaw C.E., Jennings A., Kamran R., Ueno H., Nishigaki N., Kosaka T., Tani A., Sano H., Kinugawa Y., Koumura E., Shi L., Takeuchi K. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism // PLoS One. 2016. – Vol. 11, No. 6. – Art. ID: e0157509. Published – 2016. DOI:10.1371/journal.pone.0157509; Inagaki N., Sano H., Seki Y., Kuroda S., Kaku K. Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study // J. Diabetes Investig. – 2016. – Vol. 7, No. 5. – P. 718–726. DOI:10.1111/jdi.12499; Yong X., Hu T., Feng S., Du X., Shi H., Feng W. Synergism in Pharmacokinetics of Retagliptin and Metformin Observed during Clinical Trials of their Combination Therapy // Trop J. Pharm. Res. – 2015. – Vol. 14, No. 8. – P. 1481–1486. DOI:10.4314/tjpr.v14i8.22; Chae Y.N., Kim T.H., Kim M.K., Shin C.Y., Jung I.H., Sohn Y.S., Son M.H. Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice // PLoS One. – 2015. – Vol. 10, No. 12. – Art. ID: e0144064. DOI:10.1371/journal.pone.0144064; Cho J.M., Jang H.W., Cheon H., Jeong Y.T., Kim D.H., Lim Y.M., Choi S.H., Yang E.K., Shin C.Y., Son M.H., Kim S.H., Kim H.J., Lee M.S. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis // Diabetes Res Clin Pract. – 2011. – Vol. 91, No. 1. – P. 72–79. DOI:10.1016/j.diabres.2010.10.012; Gu N., Park M.K., Kim T.E., Bahng M.Y., Lim K.S., Cho S.H., Yoon S.H., Cho J.Y., Jang I.J., Yu K.S. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers // Drug Des. Devel. Ther. – 2014. – Vol. 8. – P. 1709–1721. DOI:10.2147/DDDT.S65678; Mattei P., Boehringer M., Di Giorgio P., Fischer H., Hennig M., Huwyler J., Koçer B., Kuhn B., Loeffler B.M., Macdonald A., Narquizian R., Rauber E., Sebokova E., Sprecher U. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes // Bioorg. Med. Chem. Lett. – 2010. – Vol. 20, No. 3. – P. 1109–1113. DOI:10.1016/j.bmcl.2009.12.024; Kuhlmann O., Carlile D., Noe J., Bentley D. Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers // J. Drug Assess. –2014. – Vol. 3, No. 1. – P. 28–37. DOI:10.3109/21556660.2014.900065; https://www.pharmpharm.ru/jour/article/view/1257Test

الإتاحة: https://doi.org/10.19163/2307-9266-2023-11-1-19-47Test
https://doi.org/10.14341/DM12802Test
https://doi.org/10.1016/j.diabres.2021.109119Test
https://doi.org/10.4236/jbm.2020.88001Test
https://doi.org/10.3389/fimmu.2015.00386Test
https://doi.org/10.2337/dc07-0228Test
https://doi.org/10.1016/j.bbrc.2013.03.010Test
https://doi.org/10.2174/092986709788803114Test
https://doi.org/10.21037/atm.2018.02.24Test
https://doi.org/10.1111/jdi.13921Test

View record in BASE

8

دورية أكاديمية

The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection

المؤلفون: Peter Lindquist, Lærke Smidt Gasbjerg, Jacek Mokrosinski, Jens Juul Holst, Alexander Sebastian Hauser, Mette Marie Rosenkilde

المصدر: Frontiers in Endocrinology, Vol 13 (2022)

مصطلحات موضوعية: GIP - glucose-dependent insulinotropic peptide, missense variants, pharmacogenomics, GIPR, GPCR (G protein coupled receptor), UK Biobank, Diseases of the endocrine glands. Clinical endocrinology, RC648-665

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fendo.2022.891586/fullTest; https://doaj.org/toc/1664-2392Test

الوصول الحر: https://doaj.org/article/bf18da93d2c844fc905f0c8e2a199121Test

View record in DOAJ

النص الكامل

9

دورية أكاديمية

The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection

المؤلفون: Lindquist, Peter, Gasbjerg, Lærke Smidt, Mokrosinski, Jacek, Holst, Jens Juul, Hauser, Alexander Sebastian, Rosenkilde, Mette Marie

المصدر: Lindquist , P , Gasbjerg , L S , Mokrosinski , J , Holst , J J , Hauser , A S & Rosenkilde , M M 2022 , ' The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection ' , Frontiers in Endocrinology , vol. 13 , 891586 . https://doi.org/10.3389/fendo.2022.891586Test

مصطلحات موضوعية: GIP - glucose-dependent insulinotropic peptide, GIPR, GPCR (G protein coupled receptor), missense variants, pharmacogenomics, UK Biobank